Therapeutics Company Reaches Key FDA Agreement For IV Tramadol

Avenue Therapeutics and FDA Reach Key Agreement on Phase 3 Safety Study for IV Tramadol.

This article contains affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Avenue Therapeutics Inc. (NASDAQ: ATXI), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, has announced a significant breakthrough. The company has reach…